Skip to main content
. Author manuscript; available in PMC: 2017 Aug 1.
Published in final edited form as: Cancer Res. 2010 Feb 2;70(4):1306–1313. doi: 10.1158/0008-5472.CAN-09-2893

Fig. 2. Detection of cancer-induced auto-antibodies to MUC1 O-glycopeptide epitopes by microarray analysis.

Fig. 2

A, 3D-column diagram of IgG antibody reactivity in sera from healthy controls (n=39) and newly diagnosed patients with breast (n=26), ovarian (n=20) and prostate (n=10) cancer (Supplementary Table S1). Specific IgG responses were detected in identified breast, ovarian and prostate cancer patients towards Tn-MUC1, STn-MUC1, T-MUC1 or truncated core 3 O-glycopeptide epitopes. Only very few healthy subjects and cancer patients had IgG antibodies to AOSM and OSM, which are considered Tn and STn hapten antibodies. B, Dot-plot analysis of the antibody responses for each glycopeptide target. C, Summary of results for each MUC1 glycopeptide with indication of glycan structures and positions within the MUC1 tandem repeat. Values were considered positive if above 3 times the SD of the average value obtained with sera from healthy individuals. A total of five out of the 26 breast cancer patients showed induction of IgG auto-antibodies to either Tn, STn, T or core 3 MUC1 glycopeptides. The same reactivity pattern was seen in ovarian cancer patients with five out of 20 patients demonstrating IgG auto-antibodies to one or more of the MUC1 glycopeptides. In contrast 4 out of 10 prostate cancer patients showed induction of auto-antibodies to STn, T and, core 3 MUC1 glycopeptides. In the majority of individuals no reactivity was seen with Tn and STn MUC2 glycopeptides or AOSM and OSM.